Behavioral Health

Borderline personality disorder: management approach

Clinical Overview and When to Suspect Borderline Personality Disorder

— Impulsivity in ≥2 self-damaging areas (spending, sex, substances, binge eating, reckless driving)

— Moods reactive / affective instability (hours to days)

— Paranoid ideation or dissociation under stress (transient, stress-related)

— Unstable/intense relationships (idealization ↔ devaluation, "splitting")

— Life-threatening recurrent suicidal behavior, gestures, threats, or self-mutilation

— Self-image instability

— Inappropriate intense anger

— Void feelings (chronic emptiness)

— Efforts to avoid real/imagined abandonment

— Frequent ED visits for self-harm, overdoses, or "crisis" presentations

— Multiple prior diagnoses that "never fit" (bipolar, MDD, PTSD)

— Provider "splitting" — patient idealizes new clinician, devalues prior ones

— High utilization with low treatment adherence

— Comorbid PTSD, MDD, substance use, eating disorders, bulimia

Board pearl: Affective instability in BPD shifts in hours, triggered by interpersonal stress; bipolar mood episodes last days to weeks and are autonomous. This is the single most-tested distinction.

Step 3 management: Suspect BPD before initiating polypharmacy in a "treatment-resistant" depressed young adult with self-harm — psychotherapy referral, not another SSRI switch, is the highest-yield next step.

Definition: Pervasive pattern of instability in interpersonal relationships, self-image, and affect, plus marked impulsivity, beginning by early adulthood and present across contexts (DSM-5-TR). Requires ≥5 of 9 criteria.

The 9 criteria (mnemonic "IMPULSIVE"):

Epidemiology: Lifetime prevalence ~1.4–5.9%; ~20% of psychiatric inpatients. Female predominance in clinical samples; community samples roughly equal. Onset late adolescence to early 20s; symptoms often attenuate by age 40–50.

When to suspect (Step 3 outpatient cues):

Etiology: Heritability ~40–60%; childhood trauma/abuse/neglect in 40–70%; biosocial model (Linehan) — emotionally vulnerable temperament in invalidating environment.

Presentation Patterns and Key History

— Self-harm patterns: Non-suicidal self-injury (NSSI) — cutting, burning, scratching — typically used to regulate affect ("I feel real," "the pain releases tension"), not to die. Distinguish from suicidal intent (which also occurs; ~75% attempt, ~8–10% complete suicide).

— Relationship trajectory: Short, intense relationships; rapid intimacy; abrupt terminations triggered by perceived rejection.

— Identity disturbance: Frequent career/major/religion/sexual-orientation changes; "I don't know who I am."

— Dissociation: Stress-induced depersonalization, "spacing out," gaps in memory.

— Substance use: Often impulsive/binge pattern rather than dependence.

— Trauma history: Childhood sexual/physical abuse, neglect, invalidating environments — ask sensitively.

— Prior treatment: Multiple therapists ended in conflict; pattern of "firing" providers.

— MDD (~80% lifetime), PTSD (~30–50%), substance use (~50%), eating disorders (especially bulimia), other Cluster B (narcissistic, antisocial, histrionic).

Key distinction: NSSI ≠ suicide attempt. Both must be assessed separately at every visit. NSSI is a risk factor for suicide but is functionally distinct — assuming all cutting is suicidal leads to over-hospitalization, which is iatrogenic in BPD.

Board pearl: The phrase "splitting" (you're great, the last doctor was awful) within the first encounter is a near-pathognomonic narrative cue on USMLE stems.

Classic vignette: 22-year-old woman presents to ED after superficial wrist cutting following a breakup that occurred 6 hours ago. She tells the resident, "You're the only one who understands me — the last doctor was terrible." She has had 4 ED visits in 6 months, reports chronic emptiness, and her mood "swings hourly."

Core history domains to probe:

Comorbidity (rule, not exception):

Functional impact: Repeated job loss, unstable housing, financial impulsivity, custody issues — frame as chronic disability comparable to schizophrenia in disability-adjusted life years.

Physical Exam Findings and Mental Status Assessment

— May be dramatic, theatrical, or seductive; clothing/grooming can shift dramatically between visits reflecting identity instability.

— Look for scars in linear patterns on forearms, thighs, abdomen (cutting); cigarette burns; ligature marks on neck or wrists.

— Tattoos commemorating relationships or self-harm milestones.

— Document old vs. fresh self-injury; photograph if consent obtained and clinically indicated.

— Healed pill-bottle "track" marks unusual — substance IDU possible with comorbid SUD.

— Dental erosion / parotid swelling / Russell's sign (knuckle calluses) → comorbid bulimia.

— Appearance/behavior: May rapidly shift from tearful to angry to seductive within one interview.

— Mood/affect: Labile, reactive, intense; can switch within minutes when interpersonal content emerges.

— Thought process: Generally linear; under stress may become tangential or briefly disorganized.

— Thought content: Chronic emptiness, abandonment fears, transient paranoid ideation (e.g., "the nurse is plotting against me"); not fixed delusions.

— Perception: Stress-induced dissociation, derealization, transient quasi-psychotic phenomena (lasting minutes to hours, not days).

— Cognition: Intact orientation, memory, attention.

— Insight: Variable; often externalizes blame.

— Judgment: Impaired during affective surges, intact between.

Step 3 management: After any self-harm presentation, always check acetaminophen level even if patient denies ingestion — silent hepatotoxicity from concealed overdose is a tested pitfall.

Board pearl: Transient stress-induced micro-psychosis lasting minutes to hours is BPD; psychosis lasting days suggests schizoaffective or primary psychotic disorder.

General appearance:

Skin/extremity exam (do not skip):

Vital signs: Generally normal. Tachycardia or hypertension if acute intoxication, withdrawal, or acute distress. Always screen for overdose (acetaminophen, SSRI, benzodiazepines) when presenting after self-harm — get APAP and salicylate levels reflexively.

Mental status exam (MSE) — the highest-yield physical finding:

Diagnostic Workup — Initial Evaluation and Medical Clearance

— CBC, BMP, LFTs — baseline organ function, screen for occult overdose injury

— Acetaminophen and salicylate levels — mandatory regardless of stated ingestion

— Urine drug screen (opioids, benzos, cocaine, amphetamines, cannabinoids) — high comorbid SUD prevalence

— Ethanol level

— β-hCG in reproductive-age women — affects medication choice and disposition

— TSH — rule out thyrotoxicosis mimicking affective lability

— ECG — QTc baseline if antipsychotics or TCAs considered; also pre-overdose assessment for TCA/citalopram/methadone ingestion (wide QRS, prolonged QT)

— McLean Screening Instrument for BPD (MSI-BPD) — 10-item self-report, score ≥7 suggests BPD

— Zanarini Rating Scale (ZAN-BPD) — for severity tracking

— Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD) — gold standard

— PHQ-9 (depression), GAD-7 (anxiety), PC-PTSD-5 (trauma), AUDIT-C / DAST (substance), SCOFF (eating disorder), C-SSRS (suicide risk stratification).

CCS pearl: On a CCS case of self-harm presentation, the high-yield initial orders are: vitals q1h, acetaminophen level, salicylate level, ECG, ethanol level, UDS, CBC, BMP, LFTs, β-hCG, and a sitter / 1:1 observation — forgetting the sitter loses points.

Key distinction: Diagnosis of BPD requires symptoms present since adolescence/early adulthood across contexts — do not diagnose during a single mood episode or active intoxication.

BPD is a clinical DSM-5-TR diagnosis — there is no lab, imaging, or biomarker. Workup serves to (1) medically clear acute presentations, (2) exclude mimics, (3) screen comorbidities.

Initial labs in the ED after self-harm or crisis:

Screening instruments (outpatient):

Concurrent screening (high-yield comorbidities):

Imaging: Not routine. Consider CT head only if focal neuro deficits, head trauma, altered LOC inconsistent with intoxication, or first psychotic-like episode with atypical features.

Diagnostic Workup — Confirmatory Assessment and Rule-Outs

— SCID-5-PD (clinician-administered, gold standard)

— International Personality Disorder Examination (IPDE)

— Personality Assessment Inventory–Borderline Features Scale (PAI-BOR)

— Family, long-term partner, prior treatment records

— Pattern recognition across years > single-visit cross-section

— Documents recurrent relational chaos, identity shifts

— Thyroid disease (hyper- or hypothyroidism) — TSH, free T4

— Substance intoxication/withdrawal — UDS, ethanol, observation

— Temporal lobe epilepsy / complex partial seizures — episodic rage with postictal confusion → EEG

— Traumatic brain injury — frontal lobe disinhibition, especially with documented TBI history → consider neuropsych testing, MRI

— Wilson disease in young adults with new neuropsychiatric symptoms → ceruloplasmin, 24-hr urine copper, slit-lamp for Kayser-Fleischer rings

— HIV, syphilis (RPR), B12 deficiency if cognitive features or risk factors

— Autoimmune encephalitis (e.g., anti-NMDA receptor) — subacute psychiatric change with seizures, dyskinesias, autonomic instability → LP, anti-NMDAR antibodies

Board pearl: New-onset "BPD-like" symptoms after age 30 with no prior history should trigger a medical/neurologic workup, not a personality disorder diagnosis. True BPD is recognizable by adolescence.

Step 3 management: Obtain prior treatment records before adding a 4th psychotropic — pattern of "treatment-resistant" mood disorder in a young adult with chaotic relationships often reveals undiagnosed BPD where psychotherapy, not pharmacotherapy, is the indicated intervention.

Longitudinal observation is the true confirmatory "test." Avoid diagnosing BPD from a single ED encounter — symptoms must be enduring, pervasive, across contexts, and not better explained by another disorder, substance, or medical condition.

Structured diagnostic interviews (when diagnosis uncertain or medicolegal context):

Collateral history — under-utilized but critical:

Medical rule-outs for affective lability or impulsivity:

Neuroimaging: Not routine. MRI if focal signs, atypical course, late-onset symptoms (>30), or cognitive decline.

Risk Stratification and First-Line Management Logic

— C-SSRS or equivalent — distinguish ideation, intent, plan, behavior

— Distinguish NSSI (affect regulation, low lethality, frequent) from suicide attempt (lethal intent, planning, means)

— Risk factors for completed suicide in BPD: prior attempts, comorbid MDD/SUD, recent loss, hopelessness, older age in BPD course, command hallucinations (rare), impulsive aggression

— Outpatient (preferred default): Chronic suicidal ideation without acute escalation, established outpatient team, safety plan in place

— Brief observation / crisis stabilization unit (<72 hr): Acute escalation, intoxication, lacks safety plan

— Inpatient psychiatric admission: Imminent danger (clear intent + plan + means), failure of outpatient containment, acute psychosis, severe comorbid depression with suicidality

— Avoid prolonged hospitalization — iatrogenic regression, reinforces crisis behavior, disrupts outpatient therapy. Stays should be brief, goal-directed.

1. Evidence-based psychotherapy — DBT, MBT, TFP, schema therapy, GPM

2. Treat comorbidities (MDD, PTSD, SUD) per their own guidelines

3. Symptom-targeted pharmacotherapy for residual affective instability, impulsivity, or cognitive-perceptual symptoms

4. Care coordination — single prescriber, defined therapist, written crisis plan

5. Family psychoeducation (NEA-BPD Family Connections program)

Step 3 management: When the stem says "most appropriate next step in management" for a stable BPD patient with chronic SI — the answer is referral to dialectical behavior therapy, not medication escalation or admission.

Board pearl: Brief hospitalization beats prolonged hospitalization in BPD — long stays worsen long-term outcomes by reinforcing the sick role.

Core principle: BPD is treated primarily with psychotherapy. Pharmacotherapy is adjunctive and targets specific symptom domains or comorbidities — there is no FDA-approved medication for BPD.

Acute risk stratification (every encounter):

Disposition algorithm:

First-line treatment hierarchy:

General Psychiatric Management (GPM): Validated, scalable approach for non-DBT settings — emphasizes case management, psychoeducation about BPD as a treatable illness, focus on functional goals (work, school).

Pharmacotherapy — Symptom-Targeted Approach

— Affective dysregulation (mood lability, anger, rejection sensitivity):

— Impulsive-behavioral dyscontrol (self-harm urges, aggression, binge behaviors):

— Cognitive-perceptual symptoms (transient paranoia, dissociation, quasi-psychotic experiences):

— Benzodiazepines — paradoxical disinhibition, dependence, overdose lethality

— Tricyclics — narrow therapeutic index, lethal in overdose

— Opioids for chronic pain — high addiction/overdose risk

— Polypharmacy — common pitfall; rationalize and deprescribe

— Limited dispense quantities (1–2 weeks)

— Avoid lethal-in-overdose agents

— Single prescriber; no "splitting" between providers

Board pearl: A BPD patient on 4 psychotropics in a stem is a deprescribing question — the answer is consolidation under one prescriber and addition of structured psychotherapy.

Key distinction: Antipsychotics in BPD are low-dose, symptom-targeted, time-limited — not maintenance therapy as in schizophrenia.

Guiding principle (APA, NICE, VA/DoD): No medication treats BPD as a syndrome. Avoid polypharmacy. Target specific symptom domains with time-limited trials and re-evaluation.

Three symptom domains and preferred agents:

SSRIs — modest benefit, mostly via comorbid depression/anxiety (sertraline, fluoxetine, escitalopram)

Mood stabilizers — lamotrigine, topiramate, valproate — best evidence for impulsive aggression and anger; lamotrigine 2022 BOLD trial showed limited effect, so enthusiasm has cooled but still used

Avoid benzodiazepines — disinhibition, dependence, overdose risk

Topiramate, lamotrigine, valproate — first-line

Naltrexone — adjunct for NSSI urges, especially with comorbid AUD

SSRIs — modest

Low-dose second-generation antipsychotics — aripiprazole, olanzapine, quetiapine, risperidone

Aripiprazole has the best metabolic profile; olanzapine has strongest efficacy data but weight gain

Time-limit and reassess at 8–12 weeks

Medications to avoid or minimize:

Prescribing safety in self-harm-prone patients:

Psychotherapy — The Definitive Intervention

— Dialectical Behavior Therapy (DBT) — Linehan; best-evidenced, especially for self-harm and suicide attempts

— Mentalization-Based Therapy (MBT) — Bateman & Fonagy

— Transference-Focused Psychotherapy (TFP) — Kernberg

— Schema-Focused Therapy — Young

— General Psychiatric Management (GPM) — Gunderson

— Systems Training for Emotional Predictability and Problem Solving (STEPPS) — group-based, 20 weeks, adjunct to existing care

— Validation + change orientation

— Clear frame (frequency, fees, contact rules)

— Explicit chain analysis of self-harm episodes

— Crisis plan in writing

— Focus on functioning, not just symptom relief

Step 3 management: When DBT is unavailable in the patient's area or insurance network, GPM is the most appropriate second choice — not "continue current SSRI."

Board pearl: DBT is the only psychosocial intervention shown to reduce completed and attempted suicide in BPD across multiple RCTs — memorize this for the exam.

Evidence-based psychotherapies (all outperform treatment-as-usual; head-to-head comparisons roughly equivalent):

Structure: weekly individual therapy + weekly skills group + phone coaching + therapist consultation team

Four skill modules: mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness

Standard course: ~12 months; reduces self-harm, hospitalization, ED visits, dropout

Builds capacity to understand mental states (self/other); psychodynamically informed

Reduces self-harm and improves social function

Object relations–based; works with split internal representations as they emerge in therapeutic relationship

2x/week individual, 1+ year

Identifies and modifies early maladaptive schemas; integrates cognitive, behavioral, experiential techniques

Pragmatic, scalable, non-specialist; case management + psychoeducation + medication management

Non-inferior to DBT in some trials → realistic option when DBT unavailable

Common therapeutic stance across modalities:

Indications for higher-intensity care: Partial hospitalization or intensive outpatient programs with DBT structure when standard outpatient inadequate.

Special Populations — Elderly and Hepatic/Renal Impairment

— Symptoms often attenuate with age — impulsivity and self-harm decline by 40s–50s in ~50% (McLean and CLPS prospective studies); affective instability and emptiness more persistent.

— Late-life BPD presentations: chronic somatic complaints, healthcare overuse, conflicts with caregivers/staff in long-term care, depression, hoarding.

— Increased medical comorbidity (cardiovascular, metabolic) from years of impulsive behaviors, smoking, obesity from antipsychotics.

— Start low, go slow; renal/hepatic clearance reduced

— Avoid anticholinergics (TCAs, paroxetine, diphenhydramine) — delirium, falls, cognitive decline

— Avoid benzodiazepines — Beers Criteria; falls, hip fractures, delirium

— Antipsychotics carry boxed warning for increased mortality in dementia-related psychosis — re-evaluate need; lowest effective dose

— Monitor QTc, orthostatics, metabolic panel, fall risk

— Lithium — renally cleared, narrow therapeutic index; if used for comorbid bipolar, reduce dose, monitor levels q3 months, check creatinine

— Topiramate — reduce dose if CrCl <70; risk of nephrolithiasis

— Gabapentinoids (sometimes off-label for anxiety) — dose-adjust; also misuse risk

— SSRIs generally safe; sertraline preferred in advanced CKD

— Valproate — hepatotoxicity, contraindicated in significant liver disease; check LFTs and ammonia if encephalopathy

— Carbamazepine, lamotrigine — hepatic metabolism, dose-adjust

— Duloxetine — avoid in hepatic impairment or heavy alcohol use

— SSRIs (sertraline, citalopram) generally tolerable; avoid in decompensated cirrhosis without specialist guidance

Board pearl: In a 70-year-old long-standing BPD patient on chronic benzodiazepines presenting with falls — taper the benzodiazepine is the highest-yield management step before adjusting anything else.

Step 3 management: Annual metabolic monitoring (lipids, A1c, weight, BP) is mandatory in any BPD patient on second-generation antipsychotics — frequently tested as a quality measure.

Older adults with BPD:

Pharmacologic adjustments in elderly:

Renal impairment:

Hepatic impairment:

Special Populations — Pregnancy, Adolescents, and Cultural Considerations

— BPD increases risk of unplanned pregnancy, preterm birth, low birth weight, postpartum depression, and impaired mother-infant bonding.

— Postpartum period = high-risk window for relapse, self-harm, suicide.

— Continue psychotherapy through pregnancy; intensify postpartum follow-up.

— Medication choices:

— Coordinate OB, psychiatry, pediatrics; screen with EPDS at each prenatal and postpartum visit.

— DSM-5-TR permits BPD diagnosis in adolescents when features are pervasive, persistent (>1 year), and not better explained by developmental phase.

— Early diagnosis + DBT-A (adolescent-adapted DBT) improves outcomes; avoid diagnostic nihilism.

— Family involvement essential — multifamily skills groups, parent training.

— Screen for trauma, bullying, sexual identity stressors, online self-harm content exposure.

— Historical gender bias — BPD over-diagnosed in women, antisocial PD in men with overlapping presentations.

— LGBTQ+ patients: high rates of NSSI and BPD diagnosis may reflect minority stress; assess for trauma, discrimination, family rejection.

— Cultural expressions of distress vary — somatization, religious framing — avoid stereotyping.

Board pearl: Valproate is absolutely contraindicated in pregnancy and should generally not be used in any reproductive-age person without robust contraception — this single fact appears across psychiatry, neurology, and OB stems.

Key distinction: Postpartum mood instability with prior chronic interpersonal chaos = BPD flare; new-onset isolated postpartum mood symptoms = postpartum depression or postpartum psychosis (the latter is a medical emergency).

Pregnancy and postpartum:

Sertraline — preferred SSRI in pregnancy and breastfeeding (lowest milk transfer)

Avoid paroxetine (cardiac malformations) and valproate (neural tube defects, neurodevelopmental impairment — contraindicated in pregnancy and in any reproductive-age person not on reliable contraception)

Lamotrigine — relatively safer mood stabilizer; monitor levels, which fall in pregnancy

Quetiapine, olanzapine, aripiprazole — generally acceptable when needed

Adolescents:

Cultural and identity considerations:

Complications and Adverse Outcomes

— Lifetime suicide attempt rate ~75%; completed suicide ~8–10% — comparable to schizophrenia and major depression

— NSSI in ~70–80%; can cause permanent scarring, infection, tendon/nerve injury, hemorrhage

— Risk factors for completion: comorbid MDD, SUD, prior attempts, hopelessness, older age in BPD course, recent loss, impulsive aggression

— MDD (~80% lifetime), PTSD (30–50%), substance use disorders (~50%), eating disorders (especially bulimia, ~25%), anxiety disorders, other personality disorders

— Higher rates of obesity, diabetes, cardiovascular disease, chronic pain, fibromyalgia, IBS, chronic headaches

— Antipsychotic-related metabolic syndrome

— Sequelae of impulsive behaviors: STIs, unintended pregnancy, MVCs, traumatic injuries

— Accidental overdose during NSSI escalation

— Unemployment, underemployment, disability (~40% on disability long-term in some cohorts)

— Relationship instability, divorce, custody loss

— Legal problems from impulsivity, aggression

— Homelessness, financial ruin from impulsive spending

— Social isolation as relationships are repeatedly severed

— Iatrogenic polypharmacy with cumulative metabolic, cardiac, cognitive burden

— Iatrogenic regression from prolonged hospitalizations or unbounded therapy

— Provider burnout, splitting in treatment teams

— Premature discharge against medical advice ("flight into health")

— Remission rates 50–85% over 10–16 years (McLean Study of Adult Development, CLPS)

— Symptomatic recovery much more common than functional recovery — many remit symptomatically but remain occupationally and relationally impaired

Board pearl: BPD has higher symptomatic remission rates than chronic MDD or bipolar — communicate hope; this fact is increasingly tested and counters older nihilistic teaching.

Step 3 management: Annual cardiometabolic screening, contraception counseling, and STI screening are part of routine BPD primary care given elevated risk profile.

Suicide and self-harm:

Comorbid psychiatric illness (the rule):

Medical complications:

Functional/social complications:

Treatment-related complications:

Prognosis (more optimistic than historically taught):

When to Escalate — Hospitalization, Consults, and Crisis Triage

— Imminent suicide risk — active intent + plan + means + inability to contract for safety

— Serious suicide attempt requiring medical stabilization → psychiatric admission after medical clearance

— Acute psychosis (not transient stress-induced) or severe dissociation impairing safety

— Severe comorbid depression with suicidal features unresponsive to outpatient care

— Inability to maintain basic self-care; grave disability

— Acute substance intoxication or withdrawal complicating safety assessment

— Brief, goal-directed (typically 1–5 days)

— Specific discharge criteria written at admission

— Re-establish outpatient treatment frame

— Avoid medication overhauls during crisis — defer to outpatient prescriber when possible

— Coordinate with outpatient therapist before discharge — closed-loop communication

— Chronic SI without acute escalation in a patient with established outpatient care and safety plan

— NSSI without suicidal intent and no medical compromise

— Hospitalization as "punishment," "rescue," or response to provider anxiety alone

— Pattern of repeat admissions worsening trajectory → consider partial hospitalization or DBT-IOP instead

— Psychiatry — initial diagnostic clarification, complex pharmacotherapy, treatment-refractory cases

— DBT-trained therapist — first-line definitive treatment referral

— Substance use services — for comorbid SUD (integrated treatment preferred)

— Social work — housing, benefits, custody, legal

— Primary care coordination — cardiometabolic monitoring, contraception, preventive care

CCS pearl: For acute self-harm presentations on CCS, order medical clearance (labs, ECG, APAP level), 1:1 observation, psychiatry consult, collateral information, and outpatient provider contact before deciding disposition. Discharge with written safety plan + follow-up within 7 days scores best.

Board pearl: "Splitting" admissions where staff disagree about whether the patient is dangerous → answer is team meeting and unified treatment plan, not changing the diagnosis or medications.

Indications for psychiatric hospitalization:

Hospitalization principles in BPD:

When NOT to hospitalize:

Consultations and referrals:

Levels of care continuum: Outpatient → IOP (3 days/week) → PHP (5 days/week) → residential → inpatient. Step up briefly, step down quickly.

Key Differentials — Other Cluster B and Personality Disorders

— Shared: attention-seeking, dramatic affect, shallow/shifting emotions, sexually provocative behavior

— Key distinction: Histrionic PD lacks the self-destructiveness, identity disturbance, chronic emptiness, and intense abandonment fears of BPD. Histrionic seeks attention; BPD fears abandonment.

— Shared: anger, devaluation of others, interpersonal exploitation

— Key distinction: NPD has stable grandiosity and entitled self-image; BPD has unstable, often negative self-image. NPD reacts to narcissistic injury; BPD reacts to perceived abandonment. NPD less self-injurious.

— Shared: impulsivity, aggression, irresponsibility

— Key distinction: ASPD requires conduct disorder before age 15 and pervasive disregard for rights of others without genuine remorse. BPD typically experiences guilt, attachment, and emotional pain; ASPD does not. ASPD more male, BPD more female in clinical samples (with overlap).

— Shared: fear of being alone, need for reassurance

— Key distinction: Dependent PD is submissive and clingy; BPD oscillates between clinginess and rage. Dependent PD lacks impulsivity, identity disturbance, and self-harm.

— Shared: brief perceptual disturbances, paranoid ideation

— Key distinction: Schizotypal has persistent odd beliefs, magical thinking, and eccentric behavior; BPD has stress-induced transient paranoia/dissociation without the chronic cognitive oddities.

— Major overlap with BPD; many argue BPD = chronic relational trauma sequela in some patients

— Key distinction: PTSD requires identifiable trauma + intrusion + avoidance + hyperarousal + negative cognitions. Many patients carry both diagnoses; trauma-focused therapy (after stabilization) is indicated.

Board pearl: Identity disturbance + chronic emptiness + abandonment fears + self-harm is the BPD "fingerprint" that no other Cluster B disorder fully replicates.

Key distinction: Both BPD and bipolar disorder cause "mood swings," but only BPD has identity disturbance, chronic emptiness, and recurrent self-harm tied to interpersonal triggers.

Histrionic PD:

Narcissistic PD:

Antisocial PD:

Dependent PD:

Schizotypal PD:

Complex PTSD / disorders of extreme stress:

Key Differentials — Mood, Trauma, and Medical Mimics

— Shared: mood instability, impulsivity, irritability, suicide risk

— Key distinctions:

— Both can co-occur (~15%)

— Shared: SI, low mood, hopelessness, sleep/appetite changes

— Key distinction: MDD has persistent ≥2-week mood episodes with anhedonia; BPD has reactive emptiness and chronic SI with interpersonal triggers. Antidepressant response strong in MDD, modest in BPD.

— Shared: dissociation, emotional dysregulation, relationship problems, self-harm

— Key distinction: PTSD organized around specific trauma reminders (intrusion, avoidance, hyperarousal); BPD organized around abandonment and identity. Frequently co-occur — treat PTSD with trauma-focused therapy (PE, CPT, EMDR) after stabilization.

— Shared: impulsivity, emotional dysregulation, interpersonal problems

— Key distinction: ADHD impulsivity is trait-like, present since childhood, across all domains; BPD impulsivity is affect-driven and episodic. Stimulants risky in BPD if not coordinated.

— Can mimic affective lability, impulsivity, dissociation

— Rule: Re-evaluate personality features after ≥1 month of sobriety before confirming BPD

Board pearl: "Hours-to-days, interpersonally triggered, with identity disturbance" = BPD. "Days-to-weeks, autonomous, with sustained sleep change" = bipolar. This single distinction is the most-tested item in the topic.

Step 3 management: Before diagnosing "treatment-resistant bipolar II" in a young woman with chronic suicidality, re-evaluate for BPD — psychotherapy referral, not a 4th mood stabilizer, may be the answer.

Bipolar II disorder (the #1 tested differential):

Episode duration: Bipolar hypomania ≥4 days, depression ≥2 weeks; BPD mood shifts hours

Triggers: BPD shifts are interpersonally triggered; bipolar shifts are autonomous

Sleep: Decreased need for sleep with energy in hypomania; BPD has fragmented sleep tied to distress

Identity: Stable in bipolar; unstable in BPD

Family history: Strong for bipolar in bipolar disorder

Lithium response in bipolar; minimal in BPD

Major depressive disorder:

PTSD / complex PTSD:

ADHD:

Substance use disorders:

Medical mimics: Thyrotoxicosis, temporal lobe epilepsy, frontal lobe lesions, Huntington disease, Wilson disease, autoimmune encephalitis, traumatic brain injury, neurosyphilis, HIV-associated neurocognitive disorder.

Long-Term Plan, Secondary Prevention, and Discharge Planning

— Written safety plan (Stanley-Brown model): warning signs, internal coping strategies, social distractions, people to contact, professional contacts, means restriction

— Means restriction counseling — remove or lock firearms, limit medication supply, lockboxes

— Follow-up appointment scheduled within 7 days (ideally 48–72 hours) — this is a national quality measure

— Outpatient provider notified before discharge

— Crisis line numbers (988 Suicide and Crisis Lifeline) in writing

— Family/support involvement with patient consent

— Limited medication quantities — 1–2 week supplies; avoid lethal-in-overdose agents

— Definitive treatment: Enroll in evidence-based psychotherapy (DBT, MBT, TFP, schema, GPM) — 12+ months typical

— Medication management: Single prescriber; symptom-targeted; periodic deprescribing reviews

— Comorbidity treatment: SUD program, trauma-focused therapy after stabilization, MDD treatment

— Primary care integration: Annual labs, cardiometabolic monitoring on antipsychotics, contraception, STI screening, vaccinations

— Care coordination: Defined treatment team with regular communication; written treatment contract clarifying roles, frequency, between-session contact rules

— Means restriction (#1 evidence-based intervention)

— Lethal Means Counseling (CALM model) at every transition of care

— Caring contacts — postcards, texts, brief calls after discharge reduce repeat attempts

— DBT phone coaching for skills generalization

— Vocational rehab, supported employment, return-to-school planning

— Address financial impulsivity — payee, automatic bill pay, banking limits

— Stable housing through social work

Step 3 management: Follow-up within 7 days of psychiatric discharge is a HEDIS quality measure — on a stem about post-discharge planning, choose the earliest follow-up option.

Board pearl: Means restriction (especially firearms) is the most effective single suicide prevention intervention — ask about and document at every visit.

Discharge from inpatient or ED — required elements (CCS/Step 3 checklist):

Long-term outpatient plan:

Secondary prevention of self-harm and suicide:

Functional rehabilitation:

Follow-Up, Monitoring, and Outcomes Tracking

— Active treatment phase: weekly individual therapy (DBT/MBT/TFP) for 12+ months

— Skills group: weekly (DBT)

— Prescriber visits: every 2–4 weeks initially, then every 1–3 months when stable

— Crisis contact protocols defined in writing

— C-SSRS — suicidal ideation/behavior, NSSI urges and acts since last visit

— PHQ-9, GAD-7 — depression, anxiety severity

— ZAN-BPD or similar — BPD-specific severity tracking

— Substance use, sleep, function (work, school, relationships)

— Treatment adherence, medication side effects

— Second-generation antipsychotics: baseline and ongoing weight/BMI, waist circumference, fasting glucose/A1c, lipid panel, BP — per ADA/APA consensus (baseline, 12 weeks, then annually); AIMS exam every 6 months for tardive dyskinesia

— Mood stabilizers:

— SSRIs: assess for activation, sexual side effects, hyponatremia in elderly, QTc with citalopram >40 mg

— ECG at baseline and with dose changes for QT-prolonging agents

— Employment/school engagement

— Stable housing

— Hospitalizations and ED visits per year (key utilization metric)

— Relationship stability

— Social role functioning

— NEA-BPD Family Connections — 12-week peer-led program

— Improves caregiver burden, communication, patient outcomes

Board pearl: First lamotrigine rash → discontinue immediately and do not rechallenge — Stevens-Johnson syndrome can be fatal; this is repeatedly tested.

Step 3 management: Reduction in ED visits and hospitalizations is the most validated outcome metric in BPD treatment trials — frame value-based care goals around utilization, not just symptom scales.

Outpatient cadence:

Symptom monitoring (every visit):

Medication safety monitoring:

Valproate — LFTs, CBC, ammonia if symptoms; level q3–6 months; avoid in pregnancy

Lamotrigine — slow titration to avoid SJS/TEN; rash → stop immediately

Lithium (if used for comorbid bipolar) — level q3 months, TSH, Cr, Ca q6–12 months

Topiramate — bicarbonate, renal stones screen, cognitive side effects

Functional outcomes (track longitudinally):

Family psychoeducation:

Ethical, Legal, and Patient Safety Considerations

— BPD historically pejoratively labeled; clinicians sometimes refuse to treat citing "difficulty"

— Refusing care based on BPD diagnosis alone is ethically and legally problematic (abandonment risk)

— Frame BPD as a treatable medical condition with good evidence-based interventions — communicate hope explicitly

— Capacity must be reassessed during acute crisis or intoxication; chronic SI does not equal incapacity

— Document capacity assessment when patients refuse hospitalization or medication

— Patient with intact capacity may refuse voluntary hospitalization even with chronic SI — pursue least restrictive alternative

— Criteria vary by state but generally require mental illness + imminent danger to self/others or grave disability

— Chronic, non-imminent SI alone usually does not meet criteria

— Document specific objective findings, not diagnosis

— Right to least restrictive setting; right to refuse treatment except in emergencies

— Child abuse, elder abuse, dependent adult abuse — mandatory in all states

— Tarasoff duty — duty to protect identifiable third party from credible threat (varies by state)

— Document threat assessment, actions taken, and warnings issued

— Clear treatment frame (frequency, fees, contact rules, between-session contact policy)

— Avoid dual relationships, gifts beyond nominal value, self-disclosure beyond clinical purpose

— Document boundary discussions; use team consultation for difficult cases

— Splitting — communicate across team; unified plan in chart

— Inpatient → outpatient handoff is the highest-risk window for suicide in BPD

— Closed-loop communication, scheduled follow-up within 7 days, caring contacts, medication reconciliation with limited dispense quantities, means restriction counseling at every transition

— Risk assessment with reasoning, not just "low/medium/high"

— Safety plan documented and given to patient

— Capacity, informed consent, and refusal discussions documented verbatim where possible

Step 3 management: A patient with BPD and chronic SI who has been "fired" from multiple practices — the ethical and clinical answer is structured treatment with a clear frame, not refusal of care. Abandonment exposes the clinician to liability and worsens patient outcomes.

Board pearl: Transitions of care (ED→home, inpatient→outpatient) are the most dangerous moments — Step 3 frequently tests the 7-day follow-up and means-restriction requirements.

Stigma and the duty to treat:

Informed consent in crisis:

Involuntary commitment:

Mandatory reporting:

Boundary and frame issues:

Transition-of-care safety:

Documentation:

High-Yield Associations and Rapid-Fire Clinical Facts

— Lifetime prevalence ~1.4–5.9% general population; ~10% outpatient psychiatry; ~20% inpatient psychiatry

— Female:male ~3:1 in clinical samples; roughly equal in community samples

— Onset adolescence/early adulthood; symptomatic remission 50–85% over 10–16 years

— Heritability ~40–60%

— Amygdala hyperactivity, prefrontal hypoactivity → impaired top-down emotion regulation

— HPA axis dysregulation; possible serotonergic and opioid system dysfunction

— Childhood sexual abuse in ~40–70%; physical abuse and neglect common

— Invalidating environments (Linehan biosocial model)

— Lifetime attempts ~75%; completions ~8–10%

— NSSI in 70–80%; primary function is affect regulation

— Idealization-devaluation pattern; primitive defense

— Manifests as staff splitting in inpatient settings — team meeting is the management answer

— DBT = best evidence; reduces self-harm, suicide attempts, hospitalization

— DBT components: individual therapy, skills group, phone coaching, consultation team

— Skills modules: mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness

— GPM = scalable alternative when DBT unavailable

— No FDA-approved medication for BPD

— Symptom-targeted; avoid benzodiazepines and TCAs; avoid polypharmacy

— Antipsychotics low-dose, time-limited

— Valproate contraindicated in pregnancy

— MDD ~80%, PTSD 30–50%, SUD ~50%, eating disorders ~25%

— Younger age at treatment, fewer comorbidities, no childhood sexual abuse, no substance dependence, higher baseline functioning, engagement in evidence-based therapy

— Safety plan, means restriction, 7-day follow-up, limited dispense quantities, outpatient provider notified

Board pearl: "75/8/80" — 75% attempt suicide, 8–10% die by suicide, 80% lifetime MDD comorbidity. Memorize these three numbers.

Key distinction: Symptomatic remission in BPD is more common than in chronic MDD or bipolar — counters historical nihilism and is increasingly tested.

Epidemiology:

Genetics and neurobiology:

Trauma:

Suicide and self-harm:

Splitting:

Therapy facts:

Medication facts:

Comorbidity (lifetime):

Prognostic factors (favorable):

Discharge essentials:

Board Question Stem Patterns

— 24-year-old woman with mood shifts "from happy to suicidal within hours," triggered by texts from boyfriend, chronic emptiness, cutting scars → BPD, not bipolar II. Answer: refer to DBT.

— Patient tells you "You're the only doctor who understands me; the last one was incompetent." → Recognize splitting; answer is maintain consistent treatment frame, communicate with prior providers, do not collude with devaluation.

— Young woman on sertraline, bupropion, quetiapine, lorazepam, and lamotrigine with chronic SI and chaotic relationships → deprescribe + refer to DBT, not add a 5th medication.

— Superficial cutting after argument, denies suicidal intent, has outpatient therapist, no plan → discharge with safety plan and 7-day follow-up, not admission.

— Patient on lamotrigine develops diffuse rash with mucosal involvement → discontinue immediately, do not rechallenge.

— Reproductive-age woman with BPD on valproate planning pregnancy → discontinue valproate, switch to lamotrigine or sertraline, folate, preconception counseling.

— Nurses say patient is "manipulative"; physicians say "she's at risk." → team meeting + unified treatment plan, not changing the diagnosis.

— Patient presents post-overdose denying ingestion type → check APAP and salicylate levels regardless of stated ingestion.

— Patient cuts to "feel real" without intent to die → NSSI, not suicide attempt; outpatient management with DBT, not automatic admission.

— Discharge from psychiatric inpatient → follow-up within 7 days is the HEDIS-aligned answer.

— Rural patient without DBT access → General Psychiatric Management (GPM).

— Patient with BPD and firearm at home with chronic SI → counsel on firearm storage/removal; documented at every visit.

Board pearl: When a stem describes a chaotic young adult with self-harm, identity disturbance, and "treatment-resistant" mood symptoms, the highest-yield answer is almost always referral to dialectical behavior therapy.

Pattern 1 — Hours-to-days mood swings vs. bipolar:

Pattern 2 — Splitting in the encounter:

Pattern 3 — Polypharmacy in "treatment-resistant" depression:

Pattern 4 — Post-self-harm ED disposition:

Pattern 5 — Lamotrigine rash:

Pattern 6 — Pregnancy and valproate:

Pattern 7 — Inpatient team conflict:

Pattern 8 — Acetaminophen pitfall:

Pattern 9 — NSSI vs. suicide attempt:

Pattern 10 — Quality measure:

Pattern 11 — Choice of psychotherapy when DBT unavailable:

Pattern 12 — Means restriction:

One-Line Recap

Borderline personality disorder is a chronic but treatable syndrome of affective instability, identity disturbance, impulsivity, and abandonment-driven self-harm, best managed with evidence-based psychotherapy (DBT first-line) supported by symptom-targeted, minimally-polypharmacy pharmacotherapy, careful suicide-risk management with means restriction and 7-day post-discharge follow-up, and an integrated team that resists splitting while communicating realistic hope grounded in the high long-term remission rate.

Board pearl: When in doubt on a Step 3 BPD vignette, the correct answer set is almost always: referral to DBT, maintain treatment frame, deprescribe rather than escalate, 7-day follow-up, means restriction, and treat comorbidities by their own guidelines.

Diagnosis: ≥5 of 9 DSM-5-TR criteria; affective shifts in hours, interpersonally triggered; identity disturbance + chronic emptiness + abandonment fears + recurrent self-harm is the fingerprint that distinguishes BPD from bipolar II, MDD, PTSD, and other Cluster B disorders.

Treatment hierarchy: Evidence-based psychotherapy (DBT, MBT, TFP, schema, GPM) is definitive; no medication is FDA-approved; pharmacotherapy targets symptom domains (affective, impulsive, cognitive-perceptual) with second-generation antipsychotics, lamotrigine, topiramate, or SSRIs while strictly avoiding benzodiazepines, TCAs, and polypharmacy.

Safety and transitions: Brief goal-directed hospitalizations only; written safety plans, means restriction (especially firearms), limited medication dispensing, caring contacts, and follow-up within 7 days of any psychiatric discharge — the highest-risk window for suicide.

Prognosis and stance: 50–85% symptomatic remission over 10–16 years and 75% lifetime suicide attempts with 8–10% completion mean the clinician's stance must combine realistic hope, consistent treatment frame, team communication to defuse splitting, and longitudinal cardiometabolic and psychiatric monitoring as the patient moves through evidence-based care.